Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 2
2010 1
2011 4
2012 5
2013 4
2014 2
2015 6
2016 2
2017 5
2018 7
2019 4
2020 6
2021 4
2022 2
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group. Sands BE, et al. Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2. Lancet. 2022. PMID: 35691323 Clinical Trial.
Eosinophilic enteritis.
Pineton de Chambrun G, Desreumaux P, Cortot A. Pineton de Chambrun G, et al. Dig Dis. 2015;33(2):183-189. doi: 10.1159/000369540. Epub 2015 Apr 22. Dig Dis. 2015. PMID: 25925921 Review.
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
Louis E, Resche-Rigon M, Laharie D, Satsangi J, Ding N, Siegmund B, D'Haens G, Picon L, Bossuyt P, Vuitton L, Irving P, Viennot S, Lamb CA, Pollok R, Baert F, Nachury M, Fumery M, Gilletta C, Almer S, Ben-Horin S, Bouhnik Y, Colombel JF, Hertervig E; GETAID and the SPARE-Biocycle research group. Louis E, et al. Lancet Gastroenterol Hepatol. 2023 Mar;8(3):215-227. doi: 10.1016/S2468-1253(22)00385-5. Epub 2023 Jan 11. Lancet Gastroenterol Hepatol. 2023. PMID: 36640794 Free PMC article. Clinical Trial.
The treatment of refractory ulcerative colitis.
Pineton de Chambrun G, Tassy B, Kollen L, Dufour G, Valats JC, Bismuth M, Funakoshi N, Panaro F, Blanc P. Pineton de Chambrun G, et al. Best Pract Res Clin Gastroenterol. 2018 Feb-Apr;32-33:49-57. doi: 10.1016/j.bpg.2018.05.009. Epub 2018 May 18. Best Pract Res Clin Gastroenterol. 2018. PMID: 30060939 Review.
Diagnosis, Natural History and Treatment of Eosinophilic Enteritis: a Review.
Pineton de Chambrun G, Dufour G, Tassy B, Rivière B, Bouta N, Bismuth M, Panaro F, Funakoshi N, Ramos J, Valats JC, Blanc P. Pineton de Chambrun G, et al. Curr Gastroenterol Rep. 2018 Jul 2;20(8):37. doi: 10.1007/s11894-018-0645-6. Curr Gastroenterol Rep. 2018. PMID: 29968127 Review.
Pathogenic agents in inflammatory bowel diseases.
Pineton de Chambrun G, Colombel JF, Poulain D, Darfeuille-Michaud A. Pineton de Chambrun G, et al. Curr Opin Gastroenterol. 2008 Jul;24(4):440-7. doi: 10.1097/MOG.0b013e3283023be5. Curr Opin Gastroenterol. 2008. PMID: 18622157 Review.
Clinical implications of mucosal healing for the management of IBD.
Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel JF. Pineton de Chambrun G, et al. Nat Rev Gastroenterol Hepatol. 2010 Jan;7(1):15-29. doi: 10.1038/nrgastro.2009.203. Epub 2009 Dec 1. Nat Rev Gastroenterol Hepatol. 2010. PMID: 19949430 Review.
50 results